Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy.
Valve Center, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy.
JACC Cardiovasc Interv. 2024 Jul 22;17(14):1652-1663. doi: 10.1016/j.jcin.2024.05.002. Epub 2024 May 14.
Transcatheter aortic valve replacement (TAVR) in patients with bicuspid aortic valve (BAV) stenosis is technically challenging and is burdened by an increased risk of paravalvular regurgitation (PVR).
The aim of this study was to identify the incidence, predictors, and clinical outcomes of PVR after TAVR in Sievers type 1 BAV stenosis.
Consecutive patients with Sievers type 1 BAV stenosis undergoing TAVR with current-generation transcatheter heart valves (THVs) in 24 international centers were enrolled. PVR was graded as none/trace, mild, moderate, and severe according to echocardiographic criteria. The endpoint of major adverse events (MAEs), defined as a composite of all-cause death, stroke, or hospitalization for heart failure, was assessed at the last available follow-up.
A total of 946 patients were enrolled. PVR occurred in 423 patients (44.7%)-mild, moderate, and severe in 387 (40.9%), 32 (3.4%), and 4 (0.4%) patients, respectively. Independent predictors of moderate or severe PVR were a larger virtual raphe ring perimeter (adjusted OR: 1.07; 95% CI: 1.02-1.13), severe annular or left ventricular outflow tract calcification (adjusted OR: 5.21; 95% CI: 1.45-18.77), a self-expanding valve (adjusted OR: 9.01; 95% CI: 2.09-38.86), and intentional supra-annular THV positioning (adjusted OR: 3.31; 95% CI: 1.04-10.54). At a median follow-up of 1.3 years (Q1-Q3: 0.5-2.4 years), moderate or severe PVR was associated with an increased risk of MAEs (adjusted HR: 2.52; 95% CI: 1.24-5.09).
After TAVR with current-generation THVs in Sievers type 1 BAV stenosis, moderate or severe PVR occurred in about 4% of cases and was associated with an increased risk of MAEs during follow-up.
在二叶式主动脉瓣狭窄(BAV)患者中进行经导管主动脉瓣置换术(TAVR)在技术上具有挑战性,并且瓣周漏(PVR)的风险增加。
本研究旨在确定 Sievers 1 型 BAV 狭窄患者 TAVR 后 PVR 的发生率、预测因素和临床结局。
连续纳入 24 个国际中心的 946 例接受当前代经导管心脏瓣膜(THV)治疗的 Sievers 1 型 BAV 狭窄患者。根据超声心动图标准,将 PVR 分为无/微量、轻度、中度和重度。主要不良事件(MAEs)终点定义为全因死亡、卒中和因心力衰竭住院的复合终点,在最后一次可获得的随访中评估。
共纳入 946 例患者。423 例(44.7%)患者发生 PVR-轻度、中度和重度分别为 387 例(40.9%)、32 例(3.4%)和 4 例(0.4%)。中度或重度 PVR 的独立预测因素包括较大的虚拟隔缘环周长(校正 OR:1.07;95%CI:1.02-1.13)、严重瓣环或左心室流出道钙化(校正 OR:5.21;95%CI:1.45-18.77)、自膨式瓣膜(校正 OR:9.01;95%CI:2.09-38.86)和意向性瓣上 THV 定位(校正 OR:3.31;95%CI:1.04-10.54)。中位随访 1.3 年(Q1-Q3:0.5-2.4 年),中度或重度 PVR 与 MAEs 风险增加相关(校正 HR:2.52;95%CI:1.24-5.09)。
在 Sievers 1 型 BAV 狭窄患者中使用当前代 THV 进行 TAVR 后,约 4%的患者发生中度或重度 PVR,并且在随访期间 MAEs 风险增加。